Positive Clinical Trial Data Causes Psychedelic Biopharma Company's Shares To Nearly Double

(MENAFN- Investor Brand Network) A small Ireland-based firm, GH Research, has announced positive results from a small trial it conducted to treat treatment-resistant depression. The results from this trial revealed that their inhalable version of mebufotenin was effective and fast in delivering clinically significant improvements in the patients selected for the study. Mebufotenin is molecularly similar to psilocybin and occurs in some psychedelic mushrooms. The shares of the company jumped nearly 100% upon the release of this news.

The results of the trial were released on Monday, Jan. 3 and the trial involved...

Read More>>

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text“Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: /Disclaimer

PsychedelicNewsWire
San Francisco, CA

415.949.5050 Office
[email protected]

PsychedelicNewsWire is powered by IBN

MENAFN05022025000224011066ID1109172908